Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.

Nicole M KettnerSmruthi VijayaraghavanMerih Guray DurakTuyen BuiMehrnoosh KohansalMin Jin HaBin LiuXiayu RaoJing WangMin YiJason P W CareyXian ChenT Kris EckolsAkshara S RaghavendraNuhad K IbrahimMeghan Sri KaruturiStephanie S WatowichAysegul SahinDavid J TweardyKelly K HuntDebu TripathyKhandan Keyomarsi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Palbociclib resistance induces endocrine resistance, estrogen receptor downregulation, and alteration of IL6/STAT3 and DNA damage response pathways in cell lines and patient samples. Targeting IL6/STAT3 activity and DNA repair deficiency using a specific STAT3 inhibitor combined with a PARP inhibitor could effectively treat acquired resistance to palbociclib.

Keyphrases

dna repair
dna damage response
estrogen receptor
dna damage
cell proliferation
positive breast cancer
metastatic breast cancer
case report
cancer therapy
replacement therapy